nitpicker / Shutterstock.com
The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
On May 25, 2022, the UK Supreme Court (UKSC) handed down its judgment ([2022] UKSC 14) in the joint appeals of Pfizer and Flynn (the Appellants) against a costs ruling by the Court of Appeal (the COA Costs Ruling).
The Court of Appeal’s decision ([2020] EWCA Civ 617) had meant that public bodies and regulators such as the Competition and Markets Authority (CMA) would not typically be required to pay the costs of a party successfully appealing one of their infringement decisions.
However, the UKSC, with Lady Rose giving the lead judgment, allowed the appeal thereby confirming that the CMA is not as a matter of principle exempt from paying successful appellants’ costs. The judgment confirmed that the key criterion for assessing when a regulator may be protected from costs exposure is where requiring it to pay the successful party’s costs would give rise to a chilling effect on the regulator’s statutory activities.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
UK, Big pharma, patents, Patents, Regulators, competition, markets, authority, UK, Supreme, Court, Pfizer, Flynn
